aluates Reports

$ 0.0

Automative

Global Follicular Lymphoma Drugs Market Research Report 2026

Published Date: 2026-04-02

Report Code: QYRE-Auto-7Z9384

Global Follicular Lymphoma Drugs Market Insights and Forecast to 2028

BUY CHAPTERS

Global Follicular Lymphoma Drugs Market Research Report 2026

Code: QYRE-Auto-7Z9384

Report

2026-04-02

Pages:122

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Gilead Sciences

Secura Bio

EpiZyme Inc

Eisai Co Ltd

Acrotech Biopharma

TEVA

Eagle Pharmaceuticals

Mundipharma

Bayer

BeiGene Ltd

Pfizer Inc

Novartis

Bristol–Myers Squibb

JW Therapeutics

FOSUNKite

Follicular Lymphoma Drugs Market Size

The global Follicular Lymphoma Drugs market was valued at US$ 2103 million in 2025 and is anticipated to reach US$ 3442 million by 2032, at a CAGR of 7.4% from 2026 to 2032.

Follicular Lymphoma Drugs Market

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.

The follicular lymphoma drugs market is primarily driven by the increasing prevalence of follicular lymphoma (FL), a common and slow-growing form of non-Hodgkin lymphoma. As the global population ages, the incidence of FL is expected to rise, which boosts demand for effective treatments. Additionally, recent advancements in targeted therapies, including monoclonal antibodies like rituximab and the development of novel small molecules, have significantly improved patient outcomes and survival rates. The growing adoption of combination therapies, such as chemotherapy paired with targeted treatments or immunotherapies, has further expanded treatment options and contributed to the market's growth. The emergence of personalized medicine also enhances the potential for more tailored, effective therapies.

On the other hand, the follicular lymphoma drugs market faces challenges, including the high cost of cutting-edge therapies. Treatments such as CAR-T cell therapy and novel biologics, while effective, can be expensive and limit patient access, particularly in lower-income regions. Additionally, although FL is typically slow-growing, it is also highly recurrent, requiring long-term management and monitoring, which can strain healthcare systems. The risk of resistance to existing therapies, along with concerns over the long-term side effects of certain treatments, further complicates the landscape. Regulatory hurdles for the approval of new drugs, along with the need for ongoing research into optimizing treatment regimens, present further challenges in meeting the diverse needs of FL patients.

Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.

This report delivers a comprehensive overview of the global Follicular Lymphoma Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Follicular Lymphoma Drugs. The Follicular Lymphoma Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Follicular Lymphoma Drugs market comprehensively. Regional market sizes by Type, by Administration Route, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Follicular Lymphoma Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Administration Route, and by region.

Market Segmentation

Scope of Follicular Lymphoma Drugs Market Report

Report Metric	Details
Report Name	Follicular Lymphoma Drugs Market
Accounted market size in 2025	US$ 2103 million
Forecasted market size in 2032	US$ 3442 million
CAGR	7.4%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Anti-CD20 mAbs Chemotherapy Agents Kinase Inhibitor Others
Segment by Administration Route	Injection Oral
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Gilead Sciences, Beigene, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, MundiPharma, Pfizer, Novartis, Bristol-Myers Squibb, JW Therapeutics, FOSUNKite
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Administration Route, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Follicular Lymphoma Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Administration Route, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Follicular Lymphoma Drugs Market growing?

Ans: The Follicular Lymphoma Drugs Market witnessing a CAGR of 7.4% during the forecast period 2026-2032.

What is the Follicular Lymphoma Drugs Market size in 2032?

Ans: The Follicular Lymphoma Drugs Market size in 2032 will be US$ 3442 million.

What is the Follicular Lymphoma Drugs Market share by region?

Ans: North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.

Who are the main players in the Follicular Lymphoma Drugs Market report?

Ans: The main players in the Follicular Lymphoma Drugs Market are Roche, Gilead Sciences, Beigene, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, MundiPharma, Pfizer, Novartis, Bristol-Myers Squibb, JW Therapeutics, FOSUNKite

What are the Type segmentation covered in the Follicular Lymphoma Drugs Market report?

Ans: The Types covered in the Follicular Lymphoma Drugs Market report are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Anti-CD20 mAbs

1.2.3 Chemotherapy Agents

1.2.4 Kinase Inhibitor

1.2.5 Others

1.3 Market by Administration Route

1.3.1 Global Follicular Lymphoma Drugs Market Growth by Administration Route: 2021 vs 2025 vs 2032

1.3.2 Injection

1.3.3 Oral

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Follicular Lymphoma Drugs Market Perspective (2021–2032)

2.2 Global Follicular Lymphoma Drugs Growth Trends by Region

2.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2021–2026)

2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2027–2032)

2.3 Follicular Lymphoma Drugs Market Dynamics

2.3.1 Follicular Lymphoma Drugs Industry Trends

2.3.2 Follicular Lymphoma Drugs Market Drivers

2.3.3 Follicular Lymphoma Drugs Market Challenges

2.3.4 Follicular Lymphoma Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Follicular Lymphoma Drugs Players by Revenue

3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2021–2026)

3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Follicular Lymphoma Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Follicular Lymphoma Drugs Revenue

3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio

3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2025

3.5 Global Key Players of Follicular Lymphoma Drugs Head Offices and Areas Served

3.6 Global Key Players of Follicular Lymphoma Drugs, Products and Applications

3.7 Global Key Players of Follicular Lymphoma Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Follicular Lymphoma Drugs Breakdown Data by Type

4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2021–2026)

4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2027–2032)

5 Follicular Lymphoma Drugs Breakdown Data by Administration Route

5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2021–2026)

5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2027–2032)

6 North America

6.1 North America Follicular Lymphoma Drugs Market Size (2021–2032)

6.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Follicular Lymphoma Drugs Market Size by Country (2021–2026)

6.4 North America Follicular Lymphoma Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Follicular Lymphoma Drugs Market Size (2021–2032)

7.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Follicular Lymphoma Drugs Market Size by Country (2021–2026)

7.4 Europe Follicular Lymphoma Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2021–2032)

8.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Follicular Lymphoma Drugs Market Size (2021–2032)

9.2 Latin America Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Follicular Lymphoma Drugs Market Size by Country (2021–2026)

9.4 Latin America Follicular Lymphoma Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2021–2032)

10.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Follicular Lymphoma Drugs Introduction

11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.1.5 Roche Recent Development

11.2 Gilead Sciences

11.2.1 Gilead Sciences Company Details

11.2.2 Gilead Sciences Business Overview

11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction

11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.2.5 Gilead Sciences Recent Development

11.3 Beigene

11.3.1 Beigene Company Details

11.3.2 Beigene Business Overview

11.3.3 Beigene Follicular Lymphoma Drugs Introduction

11.3.4 Beigene Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.3.5 Beigene Recent Development

11.4 Bayer

11.4.1 Bayer Company Details

11.4.2 Bayer Business Overview

11.4.3 Bayer Follicular Lymphoma Drugs Introduction

11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.4.5 Bayer Recent Development

11.5 Secura Bio

11.5.1 Secura Bio Company Details

11.5.2 Secura Bio Business Overview

11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction

11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.5.5 Secura Bio Recent Development

11.6 Epizyme

11.6.1 Epizyme Company Details

11.6.2 Epizyme Business Overview

11.6.3 Epizyme Follicular Lymphoma Drugs Introduction

11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.6.5 Epizyme Recent Development

11.7 Eisai

11.7.1 Eisai Company Details

11.7.2 Eisai Business Overview

11.7.3 Eisai Follicular Lymphoma Drugs Introduction

11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.7.5 Eisai Recent Development

11.8 Acrotech Biopharma

11.8.1 Acrotech Biopharma Company Details

11.8.2 Acrotech Biopharma Business Overview

11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction

11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.8.5 Acrotech Biopharma Recent Development

11.9 Teva

11.9.1 Teva Company Details

11.9.2 Teva Business Overview

11.9.3 Teva Follicular Lymphoma Drugs Introduction

11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.9.5 Teva Recent Development

11.10 Eagle Pharmaceuticals

11.10.1 Eagle Pharmaceuticals Company Details

11.10.2 Eagle Pharmaceuticals Business Overview

11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction

11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.10.5 Eagle Pharmaceuticals Recent Development

11.11 MundiPharma

11.11.1 MundiPharma Company Details

11.11.2 MundiPharma Business Overview

11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction

11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.11.5 MundiPharma Recent Development

11.12 Pfizer

11.12.1 Pfizer Company Details

11.12.2 Pfizer Business Overview

11.12.3 Pfizer Follicular Lymphoma Drugs Introduction

11.12.4 Pfizer Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.12.5 Pfizer Recent Development

11.13 Novartis

11.13.1 Novartis Company Details

11.13.2 Novartis Business Overview

11.13.3 Novartis Follicular Lymphoma Drugs Introduction

11.13.4 Novartis Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.13.5 Novartis Recent Development

11.14 Bristol-Myers Squibb

11.14.1 Bristol-Myers Squibb Company Details

11.14.2 Bristol-Myers Squibb Business Overview

11.14.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Introduction

11.14.4 Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.14.5 Bristol-Myers Squibb Recent Development

11.15 JW Therapeutics

11.15.1 JW Therapeutics Company Details

11.15.2 JW Therapeutics Business Overview

11.15.3 JW Therapeutics Follicular Lymphoma Drugs Introduction

11.15.4 JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.15.5 JW Therapeutics Recent Development

11.16 FOSUNKite

11.16.1 FOSUNKite Company Details

11.16.2 FOSUNKite Business Overview

11.16.3 FOSUNKite Follicular Lymphoma Drugs Introduction

11.16.4 FOSUNKite Revenue in Follicular Lymphoma Drugs Business (2021–2026)

11.16.5 FOSUNKite Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Gilead Sciences

Secura Bio

EpiZyme Inc

Eisai Co Ltd

Acrotech Biopharma

TEVA

Eagle Pharmaceuticals

Mundipharma

Bayer

BeiGene Ltd

Pfizer Inc

Novartis

Bristol–Myers Squibb

JW Therapeutics

FOSUNKite

List of Tables

Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Anti-CD20 mAbs

Table 3. Key Players of Chemotherapy Agents

Table 4. Key Players of Kinase Inhibitor

Table 5. Key Players of Others

Table 6. Global Follicular Lymphoma Drugs Market Size Growth by Administration Route (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Follicular Lymphoma Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Follicular Lymphoma Drugs Market Size by Region (US$ Million), 2021–2026

Table 9. Global Follicular Lymphoma Drugs Market Share by Region (2021–2026)

Table 10. Global Follicular Lymphoma Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global Follicular Lymphoma Drugs Market Share by Region (2027–2032)

Table 12. Follicular Lymphoma Drugs Market Trends

Table 13. Follicular Lymphoma Drugs Market Drivers

Table 14. Follicular Lymphoma Drugs Market Challenges

Table 15. Follicular Lymphoma Drugs Market Restraints

Table 16. Global Follicular Lymphoma Drugs Revenue by Players (US$ Million), 2021–2026

Table 17. Global Follicular Lymphoma Drugs Market Share by Players (2021–2026)

Table 18. Global Top Follicular Lymphoma Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Follicular Lymphoma Drugs Revenue, 2025

Table 19. Ranking of Global Top Follicular Lymphoma Drugs Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by Follicular Lymphoma Drugs Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of Follicular Lymphoma Drugs, Headquarters and Area Served

Table 22. Global Key Players of Follicular Lymphoma Drugs, Products and Applications

Table 23. Global Key Players of Follicular Lymphoma Drugs, Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global Follicular Lymphoma Drugs Market Size by Type (US$ Million), 2021–2026

Table 26. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2021–2026)

Table 27. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2027–2032)

Table 29. Global Follicular Lymphoma Drugs Market Size by Administration Route (US$ Million), 2021–2026

Table 30. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2021–2026)

Table 31. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (US$ Million), 2027–2032

Table 32. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2027–2032)

Table 33. North America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026

Table 35. North America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032

Table 36. Europe Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026

Table 38. Europe Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific Follicular Lymphoma Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032

Table 48. Roche Company Details

Table 49. Roche Business Overview

Table 50. Roche Follicular Lymphoma Drugs Product

Table 51. Roche Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 52. Roche Recent Development

Table 53. Gilead Sciences Company Details

Table 54. Gilead Sciences Business Overview

Table 55. Gilead Sciences Follicular Lymphoma Drugs Product

Table 56. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 57. Gilead Sciences Recent Development

Table 58. Beigene Company Details

Table 59. Beigene Business Overview

Table 60. Beigene Follicular Lymphoma Drugs Product

Table 61. Beigene Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 62. Beigene Recent Development

Table 63. Bayer Company Details

Table 64. Bayer Business Overview

Table 65. Bayer Follicular Lymphoma Drugs Product

Table 66. Bayer Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 67. Bayer Recent Development

Table 68. Secura Bio Company Details

Table 69. Secura Bio Business Overview

Table 70. Secura Bio Follicular Lymphoma Drugs Product

Table 71. Secura Bio Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 72. Secura Bio Recent Development

Table 73. Epizyme Company Details

Table 74. Epizyme Business Overview

Table 75. Epizyme Follicular Lymphoma Drugs Product

Table 76. Epizyme Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 77. Epizyme Recent Development

Table 78. Eisai Company Details

Table 79. Eisai Business Overview

Table 80. Eisai Follicular Lymphoma Drugs Product

Table 81. Eisai Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 82. Eisai Recent Development

Table 83. Acrotech Biopharma Company Details

Table 84. Acrotech Biopharma Business Overview

Table 85. Acrotech Biopharma Follicular Lymphoma Drugs Product

Table 86. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 87. Acrotech Biopharma Recent Development

Table 88. Teva Company Details

Table 89. Teva Business Overview

Table 90. Teva Follicular Lymphoma Drugs Product

Table 91. Teva Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 92. Teva Recent Development

Table 93. Eagle Pharmaceuticals Company Details

Table 94. Eagle Pharmaceuticals Business Overview

Table 95. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product

Table 96. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 97. Eagle Pharmaceuticals Recent Development

Table 98. MundiPharma Company Details

Table 99. MundiPharma Business Overview

Table 100. MundiPharma Follicular Lymphoma Drugs Product

Table 101. MundiPharma Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 102. MundiPharma Recent Development

Table 103. Pfizer Company Details

Table 104. Pfizer Business Overview

Table 105. Pfizer Follicular Lymphoma Drugs Product

Table 106. Pfizer Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 107. Pfizer Recent Development

Table 108. Novartis Company Details

Table 109. Novartis Business Overview

Table 110. Novartis Follicular Lymphoma Drugs Product

Table 111. Novartis Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 112. Novartis Recent Development

Table 113. Bristol-Myers Squibb Company Details

Table 114. Bristol-Myers Squibb Business Overview

Table 115. Bristol-Myers Squibb Follicular Lymphoma Drugs Product

Table 116. Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 117. Bristol-Myers Squibb Recent Development

Table 118. JW Therapeutics Company Details

Table 119. JW Therapeutics Business Overview

Table 120. JW Therapeutics Follicular Lymphoma Drugs Product

Table 121. JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 122. JW Therapeutics Recent Development

Table 123. FOSUNKite Company Details

Table 124. FOSUNKite Business Overview

Table 125. FOSUNKite Follicular Lymphoma Drugs Product

Table 126. FOSUNKite Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026

Table 127. FOSUNKite Recent Development

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Follicular Lymphoma Drugs Picture

Figure 2. Global Follicular Lymphoma Drugs Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Follicular Lymphoma Drugs Market Share by Type: 2025 vs 2032

Figure 4. Anti-CD20 mAbs Features

Figure 5. Chemotherapy Agents Features

Figure 6. Kinase Inhibitor Features

Figure 7. Others Features

Figure 8. Global Follicular Lymphoma Drugs Market Size by Administration Route (US$ Million), 2021–2032

Figure 9. Global Follicular Lymphoma Drugs Market Share by Administration Route: 2025 vs 2032

Figure 10. Injection Case Studies

Figure 11. Oral Case Studies

Figure 12. Follicular Lymphoma Drugs Report Years Considered

Figure 13. Global Follicular Lymphoma Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global Follicular Lymphoma Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Follicular Lymphoma Drugs Market Share by Region: 2025 vs 2032

Figure 16. Global Follicular Lymphoma Drugs Market Share by Players in 2025

Figure 17. Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Follicular Lymphoma Drugs Revenue in 2025

Figure 19. North America Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America Follicular Lymphoma Drugs Market Share by Country (2021–2032)

Figure 21. United States Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Follicular Lymphoma Drugs Market Share by Country (2021–2032)

Figure 25. Germany Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Follicular Lymphoma Drugs Market Share by Region (2021–2032)

Figure 33. China Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Follicular Lymphoma Drugs Market Share by Country (2021–2032)

Figure 41. Mexico Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Follicular Lymphoma Drugs Market Share by Country (2021–2032)

Figure 45. Israel Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Roche Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 49. Gilead Sciences Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 50. Beigene Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 51. Bayer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 52. Secura Bio Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 53. Epizyme Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 54. Eisai Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 55. Acrotech Biopharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 56. Teva Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 57. Eagle Pharmaceuticals Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 58. MundiPharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 59. Pfizer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 60. Novartis Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 62. JW Therapeutics Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 63. FOSUNKite Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Hodgkin s Lymphoma Drugs Market Research Report 2024

Global Chronic Lymphocytic Leukemia Drugs Market Research Report 2024

Global Follicular Thyroid Cancer Drug Market Research Report 2025

Global Targeted Drug for Blood Cancers Market Research Report 2024

Blood Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin Lymphoma Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Follicular Lymphoma Treatment Market Research Report 2025

B Cell Non Hodgkin s Lymphoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin s Lymphoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Blood Tumor Drugs Market Research Report 2024

Global Anaplastic Large Cell Lymphoma Drugs Market Insights Forecast to 2030

Lymphoblastic Lymphoma Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Blood Tumor Treatment Market Research Report 2024

Global Mantle Cell Lymphoma Treatment Market Research Report 2025

Global Hematologic Malignancies Treatment Market Research Report 2024

Global Anaplastic Large Cell Lymphoma Treatment Market Insights Forecast to 2030

Global Mantle Cell Lymphoma Therapeutics Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions